Coagulation factor deficiency Market: Epidemiology, Therapies, Companies, DelveInsight | Novo Nordisk, Pfizer, Spark Therapeutics, Roche, Sanofi (Genzyme), Alnylam Pharmaceuticals, Sangamo Therapeutics, Biotest AG, Centessa Pharmaceuticals (Apcintex), Sta

Coagulation factor deficiency therapies, such as ESPEROCT (N8-GP; Turoctocog alfa pegol), JIVI (formerly BAY94-9027), Concizumab (NN7415), Fidanacogene elaparvovec, RG6357 (SPK-8011), and others, are expected to boost the Coagulation factor deficiency Market in the upcoming years.

DelveInsight has launched a new report on "Coagulation factor deficiency - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Coagulation factor deficiency, historical and forecasted epidemiology as well as the Coagulation factor deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Coagulation factor deficiency market report @ https://www.delveinsight.com/report-store/coagulation-factor-deficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Coagulation factor deficiency Market Report:

In 2023, the total market size for Coagulation Factor Deficiency in the 7MM was approximately USD 13.5 billion. The total number of prevalent cases of coagulation factor deficiency in the 7MM was 105,000, with the highest number of cases estimated in the United States.
In March 2024, ReciBioPharm entered into a collaboration with GeneVentiv Therapeutics, a preclinical gene therapy company, to develop an adeno-associated virus (AAV)-based universal gene therapy for hemophilia, reportedly the first aimed at treating hemophilia patients with inhibitors.
In June 2023, the US FDA accepted the Biologics License Application (BLA) for fidanacogene elaparvovec for the treatment of adults with hemophilia B. Concurrently, the European Medicines Agency (EMA) accepted the European marketing authorization application (MAA) for the same therapy, which is under review.
In 2023, there were 105,000 prevalent cases of coagulation factor deficiency across the 7MM, with the highest number of cases estimated in the United States.
In May 2023, Novo Nordisk informed the National Hemophilia Foundation about receiving a Complete Response Letter (CRL) from the FDA for their investigational subcutaneous therapy, concizumab. While Novo Nordisk had hoped for FDA approval in the Spring of 2023, the CRL indicated that additional information would delay that timeline.
Among the different types of factor-specific cases, Hemophilia A had the highest number of cases.
Key Coagulation factor deficiency companies such as Novo Nordisk, Pfizer, Spark Therapeutics, Roche, Sanofi (Genzyme), Alnylam Pharmaceuticals, Sangamo Therapeutics, Biotest AG, Centessa Pharmaceuticals (Apcintex), Staidson Biopharma Inc., GC Biopharma, Aronora, Inc., Bayer, Ultragenyx Pharmaceutical, Opko Health, Inc., and others are evaluating new drugs for Coagulation factor deficiency to improve the treatment landscape.
Promising Coagulation factor deficiency therapies include ESPEROCT (N8-GP; Turoctocog alfa pegol), JIVI (formerly BAY94-9027), Concizumab (NN7415), Fidanacogene elaparvovec, RG6357 (SPK-8011), and others.

Coagulation factor deficiency Overview

Coagulation factor deficiency diseases, also referred to as bleeding or clotting disorders, are a group of inherited or acquired conditions caused by the absence or malfunction of specific proteins required for blood clotting. These proteins, known as coagulation factors, are essential in halting bleeding by forming clots to seal damaged blood vessels.

There are several coagulation factors, numbered from I to XIII, which work together in a coordinated process to maintain hemostasis. A deficiency in any of these factors can result in abnormal bleeding, with the severity ranging from mild to severe, depending on the particular factor affected and the extent of the deficiency.

Coagulation factor deficiency Market Outlook

Recent technological advancements in the production of coagulation proteins have led to the development of modern recombinant concentrates.

Discover how the Coagulation factor deficiency market is rising in the coming years @ https://www.delveinsight.com/sample-request/coagulation-factor-deficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Coagulation factor deficiency marketed drugs:

ESPEROCT (N8-GP; Turoctocog alfa pegol): Novo Nordisk
JIVI (formerly BAY94-9027): Bayer

Coagulation factor deficiency Emerging Drugs
Concizumab (NN7415): Novo Nordisk
Fidanacogene elaparvovec: Pfizer/Spark Therapeutics
RG6357 (SPK-8011): Roche (Spark Therapeutics)

Scope of the Coagulation factor deficiency Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Coagulation factor deficiency Companies: Novo Nordisk, Pfizer, Spark Therapeutics, Roche, Sanofi (Genzyme), Alnylam Pharmaceuticals, Sangamo Therapeutics, Biotest AG, Centessa Pharmaceuticals (Apcintex), Staidson Biopharma Inc., GC Biopharma, Aronora, Inc., Bayer, Ultragenyx Pharmaceutical, Opko Health, Inc., and others
Key Coagulation factor deficiency Therapies: ESPEROCT (N8-GP; Turoctocog alfa pegol), JIVI (formerly BAY94-9027), Concizumab (NN7415), Fidanacogene elaparvovec, RG6357 (SPK-8011), and others
Coagulation factor deficiency Therapeutic Assessment: Coagulation factor deficiency current marketed and Coagulation factor deficiency emerging therapies
Coagulation factor deficiency Market Dynamics: Coagulation factor deficiency market drivers and Coagulation factor deficiency market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Coagulation factor deficiency Unmet Needs, KOL's views, Analyst's views, Coagulation factor deficiency Market Access and Reimbursement

To know what's more in our Coagulation factor deficiency report, visit https://www.delveinsight.com/report-store/coagulation-factor-deficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Coagulation factor deficiency Market Report:
Coagulation factor deficiency market report covers a descriptive overview and comprehensive insight of the Coagulation factor deficiency Epidemiology and Coagulation factor deficiency market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Coagulation factor deficiency market report provides insights into the current and emerging therapies.
The Coagulation factor deficiency market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Coagulation factor deficiency market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Coagulation factor deficiency market.

Got queries? Click here to know more about the Coagulation factor deficiency market Landscape https://www.delveinsight.com/sample-request/coagulation-factor-deficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Coagulation factor deficiency Patient Share (%) Overview at a Glance
5. Coagulation factor deficiency Market Overview at a Glance
6. Coagulation factor deficiency Disease Background and Overview
7. Coagulation factor deficiency Epidemiology and Patient Population
8. Country-Specific Patient Population of Coagulation factor deficiency
9. Coagulation factor deficiency Current Treatment and Medical Practices
10. Unmet Needs
11. Coagulation factor deficiency Emerging Therapies
12. Coagulation factor deficiency Market Outlook
13. Country-Wise Coagulation factor deficiency Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Coagulation factor deficiency Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Coagulation factor deficiency Market Outlook 2034 https://www.delveinsight.com/report-store/coagulation-factor-deficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Coagulation factor deficiency Pipeline Insights, DelveInsight

"Coagulation factor deficiency Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Coagulation factor deficiency market. A detailed picture of the Coagulation factor deficiency pipeline landscape is provided, which includes the disease overview and Coagulation factor deficiency treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.